ONCOblot® is a blood test that detects ENOX2 proteins that are only expressed from cancerous cells. ONCOblot® can determine tumour origin in 25+ cancers.
ONCOblot® is a non-invasive way to confirm the presence of cancer. It can detect cancer as early as stage 0 – an estimated 2mm or less size tumour, improving curability.
Blood is drawn locally and shipped overnight to the USA. Results are made available to Dr. Murphy in 3 weeks.
What is the ONCOblot® test?
ONCOblot® is a blood test that detects ENOX2 protein – a protein expressed only by cancer cells. It can detect ENOX2 in stage 0 – an estimated 2 million cancerous cells or 2mm or less size tumour (compared to several billion cells required for a positive mammogram).
ONCOblot® can also determine tumour origin in 25+ cancers, as each organ where malignancy arises produces a different ENOX2 protein. This is also true even if metastasis is present. For example, cancerous liver cells from metastatic lung cancer will produce ENOX2 proteins consistent with lung origin.
It is a well accepted by the medical community that early cancer detection increases chances for cure – for example, Cancer Care Ontario states that 9 out of 10 cases of colon cancer can be cured if caught early enough. ONCOblot® is considered a ‘game changer’ in secondary prevention for cancer due to its ability to detect cancer ultra early (stage 0) – making non-toxic/natural therapies more effective and conventional therapies curable.
ONCOblot® has a false positive rate of less than 1%.
How is the ONCOblot® test used?
ONCOblot® testing can confirm the presence of cancer non-invasively in the following circumstance:
Equivocal mammogram, ultrasound, CT, PET or MRI
Equivocal markers such as PSA, CEA, CA125, CA15-3, etc.
Suspicious, but non-diagnostic biopsy
Biopsy indicating cancer (second opinion)
Positive fecal occult blood
Suspicious Pap smear
ONCOblot® testing can also be used for:
Confirmation of post-treatment effectiveness
Recurrence monitoring for patients in remission
Finding tissue of origin of “cancer of unknown primary”
Other off-label uses include:
Cancer screening in high-risk populations:
- Family member with cancer (especially at a young age)
- Genetic mutation associated with increased risk (e.g. BRCA)
- Prior carcinogen exposure (e.g. smoking, radiation, chemicals, etc.)
Suspicion of cancer but patient refused biopsy
Screening for patients who cannot take mammograms due to dense breast tissue
Screening for patients in whom standard screening would be considered risky (e.g. colonoscopy in patients with cardiac problems or high perforation risk such as severe diverticulosis)
*At this time, ONOCblot® is not a replacement for screening that routinely detects pre-cancerous lesions (e.g. Pap smear and colonoscopy find dysplasia years before cancer develops).
How is the ONCOblot® test performed?
Blood is drawn at a local LifeLabs and shipped overnight to a testing laboratory in Indiana (USA). Through a partnership with Dr. Akbar Khan of Medicor Cancer Centres, results are made available to Dr. Murphy in 3 weeks.